Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVACNASDAQ:DAWNNASDAQ:ELDNNASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$3.56+4.7%$3.06$2.37▼$5.28$798.64M2.48797,524 shs679,873 shsDAWNDay One Biopharmaceuticals$7.93+4.1%$7.92$6.41▼$17.79$803.74M-1.241.06 million shs1.47 million shsELDNEledon Pharmaceuticals$3.31+0.9%$3.37$2.00▼$5.54$198.21M0.66285,376 shs96,113 shsOCSOculis$18.87+6.4%$18.13$10.79▼$23.08$823.90M0.1943,390 shs70,617 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac+4.71%+10.22%+24.48%-6.07%+34.34%DAWNDay One Biopharmaceuticals+4.07%+2.45%-0.50%-35.89%-55.17%ELDNEledon Pharmaceuticals+0.91%+2.16%0.00%-26.77%+44.54%OCSOculis+6.43%+11.00%+3.11%-17.63%+46.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac3.8685 of 5 stars3.52.00.04.81.90.01.3DAWNDay One Biopharmaceuticals2.579 of 5 stars4.60.00.00.02.72.50.0ELDNEledon Pharmaceuticals2.2085 of 5 stars3.52.00.00.03.51.70.0OCSOculis2.769 of 5 stars3.55.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 3.00Buy$14.00293.26% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$32.29307.13% UpsideELDNEledon Pharmaceuticals 3.00Buy$12.50277.64% UpsideOCSOculis 3.00Buy$30.2560.31% UpsideCurrent Analyst Ratings BreakdownLatest ELDN, DAWN, OCS, and CVAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/13/2025OCSOculisRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$37.00 ➝ $41.003/13/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/13/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $29.003/5/2025DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$39.00 ➝ $34.002/26/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.002/26/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$535.18M1.49N/AN/A$2.50 per share1.42DAWNDay One Biopharmaceuticals$131.16M6.13N/AN/A$3.98 per share1.99ELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AOCSOculis$980K840.72N/AN/A$2.87 per share6.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac-$281.58M$0.826.47N/AN/A20.72%21.98%15.72%5/22/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$1.08N/AN/AN/AN/A-22.40%-19.79%5/6/2025 (Estimated)ELDNEledon Pharmaceuticals-$116.54M-$2.36N/AN/AN/AN/A-189.99%-28.17%5/8/2025 (Estimated)OCSOculis-$98.92M-$2.31N/AN/AN/A-8,043.28%-71.31%-56.85%5/14/2025 (Estimated)Latest ELDN, DAWN, OCS, and CVAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16N/AN/AN/A$4.27 millionN/A5/14/2025Q1 2025OCSOculis-$0.50N/AN/AN/AN/AN/A5/8/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28N/AN/AN/AN/AN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.45N/AN/AN/A$30.28 millionN/A4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.056.206.19DAWNDay One BiopharmaceuticalsN/A14.6214.55ELDNEledon PharmaceuticalsN/A6.536.53OCSOculis0.014.024.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%DAWNDay One Biopharmaceuticals87.95%ELDNEledon Pharmaceuticals56.77%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipCVACCureVac2.15%DAWNDay One Biopharmaceuticals6.20%ELDNEledon Pharmaceuticals11.70%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880224.34 million219.07 millionOptionableDAWNDay One Biopharmaceuticals60101.35 million92.38 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableOCSOculis243.66 millionN/ANot OptionableELDN, DAWN, OCS, and CVAC HeadlinesRecent News About These CompaniesOculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in May 2025May 1 at 4:49 AM | quiverquant.comOculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in 2025May 1 at 4:49 AM | quiverquant.comOculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology ConferencesMay 1 at 4:00 AM | globenewswire.comOculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology ConferencesMay 1 at 4:00 AM | globenewswire.comOculis (NASDAQ:OCS) Stock Price Up 3.7% - Here's WhyApril 30 at 4:12 PM | marketbeat.comOculis Holding AG (NASDAQ:OCS) Sees Large Decrease in Short InterestApril 30 at 12:37 PM | marketbeat.comOculis (NASDAQ:OCS) Sees Strong Trading Volume - Time to Buy?April 27, 2025 | marketbeat.comOculis Updates Share CapitalApril 25, 2025 | globenewswire.comOculis (NASDAQ:OCS) Stock Price Down 2.5% - What's Next?April 24, 2025 | marketbeat.comOculis (NASDAQ:OCS) Shares Gap Up Following Analyst UpgradeApril 19, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock PriceApril 19, 2025 | marketbeat.comOculis' (OCS) Buy Rating Reaffirmed at Chardan CapitalApril 19, 2025 | marketbeat.comOculis Holding (OCS) Receives a Buy from Bank of America SecuritiesApril 17, 2025 | markets.businessinsider.comOculis and EURETINA Announce the 2025 Ramin Tadayoni AwardApril 17, 2025 | globenewswire.comOculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D DayApril 15, 2025 | tipranks.comOculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline AssetsApril 15, 2025 | globenewswire.comOculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline AssetsApril 15, 2025 | globenewswire.comOculis Holding completes enrollment in both DIAMOND phase 3 clinical trials of OCS-01 in diabetic macular edemaApril 14, 2025 | pharmabiz.comOculis completes enrollment for pivotal DME treatment trialsApril 12, 2025 | uk.investing.comOculis completes enrolment in trials for diabetic macular oedema eye dropsApril 11, 2025 | finance.yahoo.comOculis completes enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for DME eye drop candidateApril 11, 2025 | ophthalmologytimes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELDN, DAWN, OCS, and CVAC Company DescriptionsCureVac NASDAQ:CVAC$3.56 +0.16 (+4.71%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.64 +0.08 (+2.25%) As of 05/2/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Day One Biopharmaceuticals NASDAQ:DAWN$7.93 +0.31 (+4.07%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$7.93 0.00 (0.00%) As of 05/2/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Eledon Pharmaceuticals NASDAQ:ELDN$3.31 +0.03 (+0.91%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.27 -0.04 (-1.21%) As of 05/2/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Oculis NASDAQ:OCS$18.86 +1.14 (+6.40%) As of 05/2/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
